 Bolus versus infusion regimens etoposide cisplatin treatment non-small cell lung cancer study North Central Cancer Treatment group effort hypothesis duration cellular exposure cisplatin CDDP important determinant cytotoxicity phase III trial outpatient bolus regimen combined CDDP sequential infusion hours drugs patients stage IV non-small cell lung cancer survival primary end point patients study assessable response survival toxicity major response patients bolus regimen patients infusion therapy median time progression days bolus infusion therapy median survival time days Study results consistent possibility infusion therapy improvement median survival i.e months months Toxicity myelosuppression infusion regimen infusion therapy protocol CDDP advantage response rate time progression survival bolus therapy addition infusion therapy degree neutropenia treatment-related deaths